Literature DB >> 8551596

Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein.

S Kubota1, L Duan, R A Furuta, M Hatanaka, R J Pomerantz.   

Abstract

Rev, a major regulatory protein of human immunodeficiency virus type 1, has been demonstrated to shuttle between the nucleus and cytoplasm of infected cells. The fate of the Rev protein in living cells was evaluated by pulse-chase experiments using a transient Rev expression system. Sixteen hours after chasing with unlabelled amino acids, 45% of the labelled Rev was still present, which clearly indicates a long half-life of Rev in living cells. A Rev mutant which is deficient in the ability to migrate from the nucleus to the cytoplasm was degraded more slowly than the wild-type Rev protein. As well, another Rev mutant protein, which lacks a functional nucleolar targeting signal (NOS) and is unable to enter the cell nucleus, was rapidly degraded and undetectable 16 h after chasing. Nuclear-nucleolar targeting properties provided by a divergent NOS from a related retrovirus, which was used to substitute for the NOS of Rev, increased the intracellular half-life of this Rev mutant. Moreover, coexpression of an intracellular anti-Rev single-chain antibody (SFv), which has been shown to interfere with the nuclear translocation of Rev, accelerated the degradation of the wild-type Rev protein. Differential degradation of Rev in the nucleus and cytoplasm may play a critical role in determining and maintaining different stages of human immunodeficiency virus type 1 infection, in conjunction with the shuttling properties of the Rev protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551596      PMCID: PMC189944     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes.

Authors:  M H Malim; B R Cullen
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

2.  The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm.

Authors:  B E Meyer; M H Malim
Journal:  Genes Dev       Date:  1994-07-01       Impact factor: 11.361

3.  Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody.

Authors:  L Duan; O Bagasra; M A Laughlin; J W Oakes; R J Pomerantz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  HIV-1 Rev is capable of shuttling between the nucleus and cytoplasm.

Authors:  N Richard; S Iacampo; A Cochrane
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

5.  Cytotoxic activity of rev protein of human immunodeficiency virus type 1 by nucleolar dysfunction.

Authors:  T Nosaka; T Takamatsu; Y Miyazaki; K Sano; A Sato; S Kubota; M Sakurai; Y Ariumi; M Nakai; S Fujita
Journal:  Exp Cell Res       Date:  1993-11       Impact factor: 3.905

6.  The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments.

Authors:  K H Kalland; A M Szilvay; K A Brokstad; W Saetrevik; G Haukenes
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

7.  Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy.

Authors:  R A Furuta; S Kubota; M Maki; Y Miyazaki; T Hattori; M Hatanaka
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

8.  Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function.

Authors:  M Neumann; B K Felber; A Kleinschmidt; B Froese; V Erfle; G N Pavlakis; R Brack-Werner
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  Nucleocytoplasmic transport of the Rev protein of human immunodeficiency virus type 1 is dependent on the activation domain of the protein.

Authors:  B Wolff; G Cohen; J Hauber; D Meshcheryakova; C Rabeck
Journal:  Exp Cell Res       Date:  1995-03       Impact factor: 3.905

10.  Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA.

Authors:  U Fischer; S Meyer; M Teufel; C Heckel; R Lührmann; G Rautmann
Journal:  EMBO J       Date:  1994-09-01       Impact factor: 11.598

View more
  18 in total

Review 1.  Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo?

Authors:  C Salvat; C Aquaviva; I Jariel-Encontre; P Ferrara; M Pariat; A M Steff; S Carillo; M Piechaczyk
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

2.  Identification of a domain in human immunodeficiency virus type 1 rev that is required for functional activity and modulates association with subnuclear compartments containing splicing factor SC35.

Authors:  D M D'Agostino; T Ferro; L Zotti; F Meggio; L A Pinna; L Chieco-Bianchi; V Ciminale
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  The human T-cell leukemia virus Rex protein.

Authors:  Ihab Younis; Patrick L Green
Journal:  Front Biosci       Date:  2005-01-01

Review 4.  Complex mechanisms for c-fos and c-jun degradation.

Authors:  I Jariel-Encontre; C Salvat; A M Steff; M Pariat; C Acquaviva; O Furstoss; M Piechaczyk
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

5.  Mathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral components.

Authors:  Vitaly A Likhoshvai; Tamara M Khlebodarova; Sergei I Bazhan; Irina A Gainova; Valery A Chereshnev; Gennady A Bocharov
Journal:  BMC Genomics       Date:  2014-12-19       Impact factor: 3.969

6.  Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition.

Authors:  Y Wu; L Duan; M Zhu; B Hu; S Kubota; O Bagasra; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

7.  Robust growth of human immunodeficiency virus type 1 (HIV-1).

Authors:  Hwijin Kim; John Yin
Journal:  Biophys J       Date:  2005-07-29       Impact factor: 4.033

8.  Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector.

Authors:  R T Inouye; B Du; D Boldt-Houle; A Ferrante; I W Park; S M Hammer; L Duan; J E Groopman; R J Pomerantz; E F Terwilliger
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase.

Authors:  P Levy-Mintz; L Duan; H Zhang; B Hu; G Dornadula; M Zhu; J Kulkosky; D Bizub-Bender; A M Skalka; R J Pomerantz
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Diminished rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is a hallmark of human astrocytes.

Authors:  E Ludwig; F C Silberstein; J van Empel; V Erfle; M Neumann; R Brack-Werner
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.